With multiple class action lawsuits and a recent analyst downgrade, MacroGenics (MGNX) is facing significant turmoil. With the ongoing legal challenges and prevailing negative sentiment, I believe the stock will continue to experience downward pressure in the short term.

With MacroGenics facing legal and market turmoil due to allegations of misleading clinical trial data and multiple class-action lawsuits, the outlook is negative. Analysts' downgrades and potential financial penalties suggest that the stock price will continue to decline in the near future. Instead of buying shares, we are opting to buy MGNX call options.

Given the ongoing legal troubles and negative clinical trial outcomes for MacroGenics, along with analyst downgrades, I expect the stock price to remain volatile and likely decline further in the short term.